Dental and medical products company Henry Schein (NASDAQ: HSIC) will be reporting results this Tuesday morning. Here’s what investors should know.
Henry Schein missed analysts’ revenue expectations by 2% last quarter, reporting revenues of $3.17 billion, flat year on year. It was a slower quarter for the company, with a miss of analysts’ organic revenue estimates.
Is Henry Schein a buy or sell going into earnings? Read our full analysis here, it’s free.
This quarter, analysts are expecting Henry Schein’s revenue to grow 2.9% year on year to $3.23 billion, improving from the 1.2% increase it recorded in the same quarter last year. Adjusted earnings are expected to come in at $1.19 per share.
Heading into earnings, analysts covering the company have grown increasingly bearish with revenue estimates seeing 4 downward revisions over the last 30 days (we track 12 analysts).
Looking at Henry Schein’s peers in the healthcare equipment and supplies segment, some have already reported their Q2 results, giving us a hint as to what we can expect. Envista delivered year-on-year revenue growth of 7.7%, beating analysts’ expectations by 7%, and Align Technology reported a revenue decline of 1.6%, falling short of estimates by 4.8%. Envista traded up 10.1% following the results while Align Technology was down 36.8%.
Read our full analysis of Envista’s results here and Align Technology’s results here.
Debates around the economy’s health and the impact of potential tariffs and corporate tax cuts have caused much uncertainty in 2025. While some of the healthcare equipment and supplies stocks have shown solid performance in this choppy environment, the group has generally underperformed, with share prices down 4.3% on average over the last month. Henry Schein is down 7.4% during the same time and is heading into earnings with an average analyst price target of $75.85 (compared to the current share price of $67.98).
When a company has more cash than it knows what to do with, buying back its own shares can make a lot of sense–as long as the price is right. Luckily, we’ve found one, a low-priced stock that is gushing free cash flow AND buying back shares. Click here to claim your Special Free Report on a fallen angel growth story that is already recovering from a setback.
StockStory is growing and hiring equity analyst and marketing roles. Are you a 0 to 1 builder passionate about the markets and AI? See the open roles here.
